| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology.
|
Cytokine Growth Factor Rev
|
2004
|
2.72
|
|
2
|
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
|
Cytokine Growth Factor Rev
|
2004
|
2.35
|
|
3
|
Mechanisms of bone repair and regeneration.
|
Trends Mol Med
|
2009
|
1.61
|
|
4
|
Current therapeutic strategies and novel approaches in osteosarcoma.
|
Cancers (Basel)
|
2013
|
1.42
|
|
5
|
Opposite Effects of Soluble Factors Secreted by Adipose Tissue on Proliferating and Quiescent Osteosarcoma Cells.
|
Plast Reconstr Surg
|
2016
|
1.40
|
|
6
|
Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis.
|
Am J Pathol
|
2003
|
1.38
|
|
7
|
Useful side handle for holding needle during ultrasound-guided regional anesthesia.
|
Reg Anesth Pain Med
|
2009
|
1.38
|
|
8
|
Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.
|
Cancer
|
2005
|
1.30
|
|
9
|
Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling.
|
Stem Cells
|
2012
|
1.29
|
|
10
|
Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.
|
Cancer Res
|
2007
|
1.26
|
|
11
|
Recent advances in TGF-beta effects on chondrocyte metabolism. Potential therapeutic roles of TGF-beta in cartilage disorders.
|
Cytokine Growth Factor Rev
|
2002
|
1.24
|
|
12
|
Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.
|
Cancer Res
|
2010
|
1.12
|
|
13
|
Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.
|
J Pathol
|
2010
|
1.11
|
|
14
|
Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.
|
Endocrinology
|
2008
|
1.10
|
|
15
|
Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process.
|
Cancer Res
|
2010
|
1.10
|
|
16
|
Proteoglycans: key partners in bone cell biology.
|
Bioessays
|
2007
|
1.07
|
|
17
|
Concise review: embryonic stem cells: a new tool to study osteoblast and osteoclast differentiation.
|
Stem Cells
|
2006
|
1.07
|
|
18
|
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.
|
Int J Cancer
|
2006
|
1.04
|
|
19
|
OPG/membranous--RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation.
|
Bone
|
2006
|
1.02
|
|
20
|
Osteoprotegerin: multiple partners for multiple functions.
|
Cytokine Growth Factor Rev
|
2013
|
1.02
|
|
21
|
Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
|
Cancer Res
|
2009
|
1.01
|
|
22
|
Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence.
|
PLoS One
|
2010
|
1.01
|
|
23
|
Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation.
|
J Cell Mol Med
|
2009
|
1.00
|
|
24
|
Pericyte-like progenitors show high immaturity and engraftment potential as compared with mesenchymal stem cells.
|
PLoS One
|
2012
|
0.98
|
|
25
|
Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
|
J Bone Miner Res
|
2004
|
0.98
|
|
26
|
Oxytocin reverses ovariectomy-induced osteopenia and body fat gain.
|
Endocrinology
|
2014
|
0.96
|
|
27
|
Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
|
Oncol Rep
|
2007
|
0.96
|
|
28
|
Autophagy in osteoblasts is involved in mineralization and bone homeostasis.
|
Autophagy
|
2014
|
0.96
|
|
29
|
Carotid and femoral atherosclerotic plaques show different morphology.
|
Atherosclerosis
|
2011
|
0.96
|
|
30
|
Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.
|
Clin Cancer Res
|
2010
|
0.96
|
|
31
|
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
|
Int J Oncol
|
2006
|
0.95
|
|
32
|
A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis.
|
Arthritis Res Ther
|
2009
|
0.94
|
|
33
|
BYL719, a new α-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma.
|
Int J Cancer
|
2014
|
0.94
|
|
34
|
Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment.
|
Int J Cancer
|
2014
|
0.94
|
|
35
|
Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis.
|
Joint Bone Spine
|
2010
|
0.93
|
|
36
|
Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats.
|
Cancer Res
|
2008
|
0.91
|
|
37
|
First preclinical imaging of primary cartilage neoplasm and its local recurrence using 99mTc-NTP 15-5 radiotracer.
|
J Nucl Med
|
2009
|
0.90
|
|
38
|
Differentiation of osteoblasts from mouse embryonic stem cells without generation of embryoid body.
|
In Vitro Cell Dev Biol Anim
|
2007
|
0.90
|
|
39
|
Mifamurtide for the treatment of nonmetastatic osteosarcoma.
|
Expert Opin Pharmacother
|
2011
|
0.89
|
|
40
|
mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours.
|
Curr Med Chem
|
2007
|
0.89
|
|
41
|
Proteoglycans on bone tumor development.
|
Drug Discov Today
|
2010
|
0.89
|
|
42
|
Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.
|
Mol Cancer Ther
|
2008
|
0.89
|
|
43
|
Distinct roles of Bcl-2 and Bcl-Xl in the apoptosis of human bone marrow mesenchymal stem cells during differentiation.
|
PLoS One
|
2011
|
0.88
|
|
44
|
TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.
|
Am J Cancer Res
|
2011
|
0.88
|
|
45
|
Osteosarcoma: current status of immunotherapy and future trends (Review).
|
Oncol Rep
|
2006
|
0.87
|
|
46
|
RANKL/RANK/OPG: key therapeutic target in bone oncology.
|
Curr Drug Discov Technol
|
2008
|
0.87
|
|
47
|
Molecular alterations associated with osteosarcoma development.
|
Sarcoma
|
2012
|
0.86
|
|
48
|
Formulated siRNAs targeting Rankl prevent osteolysis and enhance chemotherapeutic response in osteosarcoma models.
|
J Bone Miner Res
|
2011
|
0.86
|
|
49
|
Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.
|
J Biol Chem
|
2009
|
0.86
|
|
50
|
TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.
|
Future Oncol
|
2015
|
0.86
|
|
51
|
Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells.
|
PLoS One
|
2012
|
0.85
|
|
52
|
Mechanistic study of the proangiogenic effect of osteoprotegerin.
|
Angiogenesis
|
2013
|
0.85
|
|
53
|
Impact of oncopediatric dosing regimen of zoledronic acid on bone growth: preclinical studies and case report of an osteosarcoma pediatric patient.
|
J Bone Miner Res
|
2011
|
0.84
|
|
54
|
Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds.
|
Cytokine
|
2012
|
0.84
|
|
55
|
Direct anti-cancer effect of oncostatin M on chondrosarcoma.
|
Int J Cancer
|
2011
|
0.84
|
|
56
|
Mesomelia-synostoses syndrome results from deletion of SULF1 and SLCO5A1 genes at 8q13.
|
Am J Hum Genet
|
2010
|
0.84
|
|
57
|
Regulation and function of immunosuppressive molecule human leukocyte antigen G5 in human bone tissue.
|
FASEB J
|
2013
|
0.83
|
|
58
|
Hamstring insertion site healing after anterior cruciate ligament reconstruction in patients with symptomatic hardware or repeat rupture: a histologic study in 12 patients.
|
Arthroscopy
|
2003
|
0.83
|
|
59
|
Oncostatin M is a growth factor for Ewing sarcoma.
|
Am J Pathol
|
2012
|
0.83
|
|
60
|
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
|
BMC Cancer
|
2014
|
0.83
|
|
61
|
Modulatory effects of proteoglycans on proteinase activities.
|
Methods Mol Biol
|
2012
|
0.83
|
|
62
|
New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance.
|
Lab Invest
|
2013
|
0.82
|
|
63
|
Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells.
|
Bone
|
2009
|
0.82
|
|
64
|
Osteoclasts in RA: diverse origins and functions.
|
Joint Bone Spine
|
2013
|
0.81
|
|
65
|
Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases.
|
Expert Rev Anticancer Ther
|
2008
|
0.81
|
|
66
|
Osteoprotegerin: a new therapeutic agent for the treatment of bone disease.
|
Drug Discov Today
|
2001
|
0.81
|
|
67
|
The vertebral interbody grafting site's low concentration in osteogenic progenitors can greatly benefit from addition of iliac crest bone marrow.
|
Eur Spine J
|
2005
|
0.80
|
|
68
|
Glycosaminoglycans inhibit the adherence and the spreading of osteoclasts and their precursors: role in osteoclastogenesis and bone resorption.
|
Eur J Cell Biol
|
2010
|
0.79
|
|
69
|
Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo.
|
Clin Cancer Res
|
2008
|
0.79
|
|
70
|
Conditioned media from mouse osteosarcoma cells promote MC3T3-E1 cell proliferation using JAKs and PI3-K/Akt signal crosstalk.
|
Cancer Sci
|
2008
|
0.79
|
|
71
|
Pharmacodynamics of bisphosphonates in arthritis.
|
Expert Rev Clin Pharmacol
|
2011
|
0.78
|
|
72
|
Orthopaedic implant failure: aseptic implant loosening--the contribution and future challenges of mouse models in translational research.
|
Clin Sci (Lond)
|
2014
|
0.78
|
|
73
|
Pre-clinical studies of bone regeneration with human bone marrow stromal cells and biphasic calcium phosphate.
|
Stem Cell Res Ther
|
2014
|
0.78
|
|
74
|
A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.
|
Mol Cancer Res
|
2012
|
0.78
|
|
75
|
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
|
Cancer
|
2011
|
0.78
|
|
76
|
Computational model combined with in vitro experiments to analyse mechanotransduction during mesenchymal stem cell adhesion.
|
Eur Cell Mater
|
2013
|
0.78
|
|
77
|
Proteoglycans and osteolysis.
|
Methods Mol Biol
|
2012
|
0.77
|
|
78
|
Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?
|
Expert Opin Emerg Drugs
|
2013
|
0.77
|
|
79
|
OPG, RANK and RANK ligand expression in thyroid lesions.
|
Regul Pept
|
2008
|
0.77
|
|
80
|
Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis.
|
Biochim Biophys Acta
|
2013
|
0.77
|
|
81
|
Bisphosphonates and bone diseases: past, present and future.
|
Curr Pharm Des
|
2010
|
0.76
|
|
82
|
Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
|
Int J Cancer
|
2008
|
0.76
|
|
83
|
Novel RANK antagonists for the treatment of bone-resorptive disease: theoretical predictions and experimental validation.
|
J Bone Miner Res
|
2014
|
0.76
|
|
84
|
A"Proteoglycan targeting strategy" for the scintigraphic imaging and monitoring of the swarm rat chondrosarcoma orthotopic model.
|
Sarcoma
|
2011
|
0.75
|
|
85
|
99mTc-NTP 15-5 assessment of the early therapeutic response of chondrosarcoma to zoledronic acid in the Swarm rat orthotopic model.
|
EJNMMI Res
|
2013
|
0.75
|
|
86
|
Extraosseous bone formation obtained by association of mesenchymal stem cells with a periosteal flap in the rat.
|
Ann Plast Surg
|
2007
|
0.75
|
|
87
|
Quaternary ammonium-melphalan conjugate for anticancer therapy of chondrosarcoma: in vitro and in vivo preclinical studies.
|
Invest New Drugs
|
2011
|
0.75
|
|
88
|
Novel anti-cancer strategy in bone tumors by targeting molecular and cellular modulators of bone resorption.
|
Recent Pat Anticancer Drug Discov
|
2008
|
0.75
|
|
89
|
Effect of adding bone marrow to ceramic graft materials with different interconnectivities in lumbar arthrodesis : quantification of bone formation.
|
J Orthop Sci
|
2012
|
0.75
|
|
90
|
Relevance of the POS-1 orthotopic model as an "imaging model" for in vivo and simultaneous monitoring of tumor proliferation and bone remodeling in osteosarcoma.
|
Cancer Biother Radiopharm
|
2012
|
0.75
|